Characteristics | Vimentin methylation | p | |
Negative (n = 32) | Positive (n = 18) | ||
Age (years) |
|
|
|
≤50 | 16 (50.0%) | 9 (50.0%) | 1.000 |
>50 | 16 (50.0%) | 9 (50.0%) | |
Tumor size (cm) |
|
|
|
<3 | 12 (37.5%) | 5 (27.8%) | 0.486 |
≥3 | 20 (62.5) | 13 (72.2) | |
LN metastasis |
|
|
|
Negative | 17 (53.1%) | 10 (55.6%) |
|
Positive | 15 (46.9%) | 8 (44.4%) | |
Vas invasion |
|
|
|
Positive | 25 (78.1%) | 14 (77.8%) | 1.000 |
Negative | 7 (21.9%) | 4 (22.2%) | |
Her 2 neu |
|
|
|
Negative | 20 (62.5%) | 11 (61.1%) | 0.923 |
Positive | 12 (37.5%) | 7 (38.9%) | |
P R |
|
|
|
Negative | 11 (34.4%) | 1 (5.6%) | 0.036* |
Positive | 21 (65.6%) | 17 (94.4%) | |
E R |
|
|
|
Negative | 12 (37.5%) | 2 (11.1%) | 0.046 |
Positive | 20 (62.5%) | 16 (88.9%) | |
Subtypes |
|
|
|
TNBC | 11 (34.4%) | 0 (0.0%) | 0.004* |
Non TNBC | 21 (65.6%) | 18 (100.0%) | |
TNM stage |
|
|
|
Stage II | 17 (53.1%) | 13 (72.2%) | 0.186 |
Stage III | 15 (46.9%) | 5 (27.8%) | |
Serum vimentin (ng/ml) | 1385.34 ± 537.25 | 688.89 ± 480.09 | <0.001* |
Serum Ca 15-3 | 53.38 ± 16.17 | 47.44 ± 13.03 | 0.190 |